FROM: Schulman IRB ("Schulman" or the "Board")
TO: All sites that receive Schulman approval to conduct this protocol
SUBJECT: Recruitment/Study-Related Material
IRB NO.: 201402563;
SPONSOR: National Bone Health Alliance
PROTOCOL NO.: NBHADH1

The following item was reviewed by Expedited Review, as referenced below, and received a decision of

Approved for use ONLY in its entirety

<table>
<thead>
<tr>
<th>Material Type</th>
<th>Flyer</th>
<th>Material Item#</th>
<th>MA1608063-1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Description</td>
<td>Flyer for print in office and online advertising</td>
<td>Received Via</td>
<td>Email</td>
</tr>
<tr>
<td>Submitted By</td>
<td>Sponsor</td>
<td>Review Date</td>
<td>11/03/2016</td>
</tr>
<tr>
<td>Received Date</td>
<td>11/01/2016</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Approved and/or Acknowledged Recruitment/Study-Related materials should not be used or distributed to study subjects until you have received an approval letter from Schulman to conduct this study.

Acknowledged material includes, but is not limited to, copyrighted documents, some subject instructions, standardized questionnaires, etc.

Any variation of approved or acknowledged materials must be resubmitted as outlined in the Recruitment Guidance available at www.sairb.com.

PLEASE REFERENCE MATERIAL ITEM NUMBER MA1608063-1 ON ALL CORRESPONDENCE

WebPortal/Paperless
Are you currently taking Fosamax or Actonel (alendronate or risedronate) for your Osteoporosis and curious if it is time for a “Drug Holiday”? If so you may be eligible to participate in a “Drug Holiday” clinical research study to monitor patients who have been treated for 5 years with Fosamax or Actonel for Osteoporosis.

Qualified participants will receive

• Study related visit’s, DXA’s, & Laboratory work
• Compensation may be available for you time and travel

Please contact XXXXXXXXXXXXXXXX at xxx-xxx-xxxx to see if you may qualify.